---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-26-000048"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2026-06-17T12:03:10+00:00"
generated_at: "2026-06-17T12:05:24.337658+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Elicio reports 3 complete responses post-ELI-002 7P with checkpoint inhibition in mPDAC

## Summary
- 100% confirmed complete radiographic and metabolic responses in 3 patients who progressed on ELI-002 7P and received nivolumab-based therapy.
- Complete responses rarely observed (0-8%) in metastatic pancreatic cancer; all 3 patients are MSS/MMR-p, historically refractory to immunotherapy.
- Two patients maintained complete responses ≥8 months; one ongoing >13 months with persistent mKRAS-specific T cells.
- Elicio plans Phase 1 study in first-line metastatic mKRAS PDAC combining ELI-002 7P with chemotherapy and anti-PD-1, subject to funding.
- Virtual KOL event June 24, 2026, to discuss observations with UCLA and University of Miami oncologists.

## SEC filing metadata
- accession: 0001601485-26-000048
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2026-06-17T12:03:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000048/0001601485-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000048/angn-20260617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-26-000048
- JSON: https://secwatch.observer/filing/0001601485-26-000048.json
- Plain text: https://secwatch.observer/filing/0001601485-26-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.